IL‐6 promoter polymorphism in patients with rheumatoid arthritis

References

• Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995;86:1243–54.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1987;86:5953–7.
   Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924–8.
   PubMed Web of Science ®Google Scholar
• Sack U, Kinne R, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45–51.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997;40:1096–105.
   PubMed Web of Science ®Google Scholar
• Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001;72:1444–50.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight joint counts. Develop-ment and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity mea-sures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729–40.
   PubMed Web of Science ®Google Scholar
• Donn RP, Barrett JH, Farhan A, Stopford A, Pepper L, Shelley E, et al. Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. British Paediatric Rheumatology Study Group. Arthritis Rheum 2001;44:802–10.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102: 1369–76.
   Google Scholar
• Endler G, Marsik C, Joukhadar C, Marculescu R, Mayr F, Mannhalter C, et al. The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 con-centrations in experimental endotoxemia in humans. Clin Chem 2004;50:195–200.
   PubMed Web of Science ®Google Scholar
• Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immunol 2000;1: 338–40.
   Google Scholar
• Jordanides N, Eskdale J, Stuart R, Gallaghner G. Allele associations reveal four prominent haplotypes at the human interleukin (IL-6) locus. Genes Immunol 2000; 1:451–5.
   PubMed Web of Science ®Google Scholar
• Terrey CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regula-tion. J Biol Chem 2000;275: 18138–44.
   Google Scholar
• Barrera P, Boerbooms AMT, Janssen EM, Sauerwein RW, Gallati H, Mulder J, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070–9.
   PubMed Web of Science ®Google Scholar
• Crily A, McInness IB, McDonald AG, Watson J, Cape11 HA, Madhok R. Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 1995;22: 224–6.
   Google Scholar
• Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003;48:3202–6.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991;17:891–905.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin 6 levels with joint involvement and the thrombocytosis in systemic juvenile chronic arthritis. Arthritis Rheum 1991;34:1158–63.
   PubMed Web of Science ®Google Scholar
• Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kulfersch F, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation para-meters and clinical subtypes. Arthritis Rheum 1995;38:211–20.
   Google Scholar
• Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodan M. Study of IL-2, IL-6, TNF alpha IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheum 1994;12:561–5.
   PubMed Web of Science ®Google Scholar
• Madhok R, Crilly A, Watson J, Cape11 HA. Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52: 232–4.
   Google Scholar
• Dahlqvist SR, Arlestig L, Sikstrom C, Linghult S. Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (-174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden. Arthritis Rheum 2002;46:3096–8.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989;74:1241–4.
   PubMed Web of Science ®Google Scholar
• Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998;95:8222–6.
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal anti-body in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 200;46:3143-50.
   Google Scholar
• Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal anti-body. J Rheumatol 1993;20: 259–62.
   Google Scholar